{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:14:08Z","timestamp":1793315648059,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent progress in the treatment, the outcome of adult acute T-cell lymphoblastic leukemia (T-ALL) is poor. Development of novel approach to combat this disease is urgently required. Vorinostat, a pan-histone deacetylase (HDAC) inhibitor, exerts promising anticancer activity in a variety of solid and hematologic malignancies. However, the efficacy of vorinostat monotherapy is unsatisfactory. Here, we show that quinacrine (QC), an anti-malaria drug with potent autophagy inhibitory activity, could synergistically enhance vorinostat-induced cell death at a non-toxic concentration. Compared to the single treatment, QC plus vorinostat significantly induced apoptosis, disrupted the mitochondrial transmembrane potential, and decreased Mcl-1 and Bcl-2\/Bax ratio. Interestingly, the application of QC plus vorinostat resulted in mitophagy blockade, as reflected by the increase in the K63-linked ubiquitination of mitochondria protein and the formation of mitochondrial aggresomes. QC plus vorinostat markedly increased the reactive oxygen species (ROS) level in cells. Moreover, the ROS scavenger<jats:italic>N<\/jats:italic>-acetylcysteine (NAC) abrogated QC plus vorinostat-induced ROS, decreased the ubiquitination of mitochondria proteins, and cell death. Finally, using a xenograft mouse model, we demonstrated that QC plus vorinostat significantly reduced cell proliferation and induced cell death in vivo. Taken together, our results showed that the combination of QC with vorinostat may represent a novel regimen for the treatment of T-cell acute lymphoblastic leukemia, which deserves clinical evaluation in the future.<\/jats:p>","DOI":"10.1038\/s41419-018-0679-6","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T11:37:25Z","timestamp":1526989045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition"],"prefix":"10.1038","volume":"9","author":[{"given":"Bo","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-8757","authenticated-orcid":false,"given":"Yingli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"679_CR1","doi-asserted-by":"publisher","first-page":"E1904","DOI":"10.3390\/ijms18091904","volume":"18","author":"D Bongiovanni","year":"2017","unstructured":"Bongiovanni, D., Saccomani, V. & Piovan, E. Aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Int. J. Mol. Sci. 18, E1904 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"679_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2017.07.019","volume":"405","author":"SA Moharram","year":"2017","unstructured":"Moharram, S. A. et al. Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia. Cancer Lett. 405, 73\u201378 (2017).","journal-title":"Cancer Lett."},{"key":"679_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bbrc.2015.06.145","volume":"464","author":"K Lu","year":"2015","unstructured":"Lu, K. et al. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells. Biochem. Biophys. Res. Commun. 464, 292\u2013298 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"679_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-8722-3-5","volume":"3","author":"J Tan","year":"2010","unstructured":"Tan, J., Cang, S., Ma, Y., Petrillo, R. L. & Liu, D. Novel histone deacetylase inhibitors in clinical trials as anticancer agents. J. Hematol. Oncol. 3, 5 (2010).","journal-title":"J. Hematol. Oncol."},{"key":"679_CR5","first-page":"462","volume":"10","author":"M Lemoine","year":"2010","unstructured":"Lemoine, M. & Younes, A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov. Med. 10, 462\u2013470 (2010).","journal-title":"Discov. Med."},{"key":"679_CR6","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjh.12819","volume":"165","author":"M Ogura","year":"2014","unstructured":"Ogura, M. et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br. J. Haematol. 165, 768\u2013776 (2014).","journal-title":"Br. J. Haematol."},{"key":"679_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1517\/13543784.2016.1164140","volume":"25","author":"S Apuri","year":"2016","unstructured":"Apuri, S. & Sokol, L. An overview of investigational histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin\u2019s lymphoma. Expert Opin. Investig. Drugs 25, 687\u2013696 (2016).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"679_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-015-0151-8","volume":"7","author":"C Zhang","year":"2015","unstructured":"Zhang, C. et al. Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clin. Epigenet. 7, 117 (2015).","journal-title":"Clin. Epigenet."},{"key":"679_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00432-015-2026-y","volume":"142","author":"K Xue","year":"2016","unstructured":"Xue, K. et al. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. J. Cancer Res. Clin. Oncol. 142, 379\u2013387 (2016).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"679_CR10","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1007\/s13277-015-3156-1","volume":"36","author":"B Yang","year":"2015","unstructured":"Yang, B. et al. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo. Tumour Biol. 36, 5051\u20135061 (2015).","journal-title":"Tumour Biol."},{"key":"679_CR11","first-page":"5287","volume":"34","author":"N Kunami","year":"2014","unstructured":"Kunami, N., Katsuya, H., Nogami, R., Ishitsuka, K. & Tamura, K. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia\/lymphoma. Anticancer Res. 34, 5287\u20135294 (2014).","journal-title":"Anticancer Res."},{"key":"679_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bcp.2016.01.017","volume":"105","author":"R Preet","year":"2016","unstructured":"Preet, R. et al. Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem. Pharmacol. 105, 23\u201333 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"679_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4161\/cbt.12.3.17033","volume":"12","author":"W Wang","year":"2011","unstructured":"Wang, W. et al. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol. Ther. 12, 229\u2013238 (2011).","journal-title":"Cancer Biol. Ther."},{"key":"679_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/EDE.0b013e3181cb41c8","volume":"21","author":"DC Sokal","year":"2010","unstructured":"Sokal, D. C. et al. Quinacrine sterilization and gynecologic cancers: a case\u2013control study in northern Vietnam. Epidemiology 21, 164\u2013171 (2010).","journal-title":"Epidemiology"},{"key":"679_CR15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1166\/jbn.2015.2079","volume":"11","author":"MG Sun","year":"2015","unstructured":"Sun, M. G. et al. Targeting epirubicin plus quinacrine liposomes modified with DSPE-PEG2000-C(RGDfK) conjugate for eliminating invasive breast cancer. J. Biomed. Nanotechnol. 11, 1339\u20131353 (2015).","journal-title":"J. Biomed. Nanotechnol."},{"key":"679_CR16","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/bjc.1997.272","volume":"75","author":"PL de Souza","year":"1997","unstructured":"de Souza, P. L., Castillo, M. & Myers, C. E. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br. J. Cancer 75, 1593\u20131600 (1997).","journal-title":"Br. J. Cancer"},{"key":"679_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4161\/cbt.12.3.17034","volume":"12","author":"JN Gallant","year":"2011","unstructured":"Gallant, J. N. et al. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol. Ther. 12, 239\u2013251 (2011).","journal-title":"Cancer Biol. Ther."},{"key":"679_CR18","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.18632\/oncotarget.2869","volume":"6","author":"P Song","year":"2015","unstructured":"Song, P. et al. Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells. Oncotarget 6, 3861\u20133873 (2015).","journal-title":"Oncotarget"},{"key":"679_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.taap.2015.02.005","volume":"284","author":"JJ Changchien","year":"2015","unstructured":"Changchien, J. J. et al. Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK\/c-Jun-mediated BCL2L1 expression. Toxicol. Appl. Pharmacol. 284, 33\u201341 (2015).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"679_CR20","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.4161\/cc.8.23.10179","volume":"8","author":"N Neznanov","year":"2009","unstructured":"Neznanov, N. et al. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 8, 3960\u20133970 (2009).","journal-title":"Cell Cycle"},{"key":"679_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1472-8206.2008.00613.x","volume":"22","author":"GW Liang","year":"2008","unstructured":"Liang, G. W. et al. Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fund. Clin. Pharmacol. 22, 429\u2013437 (2008).","journal-title":"Fund. Clin. Pharmacol."},{"key":"679_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.molcel.2014.09.007","volume":"56","author":"A Ordureau","year":"2014","unstructured":"Ordureau, A. et al. Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Mol. Cell. 56, 360\u2013375 (2014).","journal-title":"Mol. Cell.."},{"key":"679_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/cells3041027","volume":"3","author":"Z Erpapazoglou","year":"2014","unstructured":"Erpapazoglou, Z., Walker, O. & Haguenauer-Tsapis, R. Versatile roles of k63-linked ubiquitin chains in trafficking. Cells 3, 1027\u20131088 (2014).","journal-title":"Cells"},{"key":"679_CR24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.bmcl.2017.01.025","volume":"27","author":"ND Idippily","year":"2017","unstructured":"Idippily, N. D., Gan, C., Orefice, P., Peterson, J. & Su, B. Synthesis of vorinostat and cholesterol conjugate to enhance the cancer cell uptake selectivity. Bioorg. Med. Chem. Lett. 27, 816\u2013820 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"679_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-015-0176-7","volume":"8","author":"MW Chao","year":"2015","unstructured":"Chao, M. W. et al. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J. Hematol. Oncol. 8, 82 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"679_CR26","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/bjc.2017.33","volume":"116","author":"R Pili","year":"2017","unstructured":"Pili, R. et al. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I\/II clinical trial. Br. J. Cancer 116, 874\u2013883 (2017).","journal-title":"Br. J. Cancer"},{"key":"679_CR27","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1182\/blood-2013-05-500629","volume":"122","author":"ML Torgersen","year":"2013","unstructured":"Torgersen, M. L., Engedal, N., Boe, S. O., Hokland, P. & Simonsen, A. Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells. Blood 122, 2467\u20132476 (2013).","journal-title":"Blood"},{"key":"679_CR28","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2014.12.FOCUS14748","volume":"38","author":"EB Golden","year":"2015","unstructured":"Golden, E. B. et al. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg. Focus 38, E12 (2015).","journal-title":"Neurosurg. Focus"},{"key":"679_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.31","volume":"5","author":"A Eriksson","year":"2015","unstructured":"Eriksson, A. et al. Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J. 5, e307 (2015).","journal-title":"Blood Cancer J."},{"key":"679_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/leu.2010.315","volume":"25","author":"H Hasegawa","year":"2011","unstructured":"Hasegawa, H. et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia\/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 25, 575\u2013587 (2011).","journal-title":"Leukemia"},{"key":"679_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/jb\/mvp122","volume":"146","author":"T Tatsuta","year":"2009","unstructured":"Tatsuta, T. Protein quality control in mitochondria. J. Biochem. 146, 455\u2013461 (2009).","journal-title":"J. Biochem."},{"key":"679_CR32","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1042\/BST0391509","volume":"39","author":"EB Taylor","year":"2011","unstructured":"Taylor, E. B. & Rutter, J. Mitochondrial quality control by the ubiquitin-proteasome system. Biochem. Soc. Trans. 39, 1509\u20131513 (2011).","journal-title":"Biochem. Soc. Trans."},{"key":"679_CR33","doi-asserted-by":"crossref","first-page":"3165396","DOI":"10.1155\/2017\/3165396","volume":"2017","author":"Y Kim","year":"2017","unstructured":"Kim, Y., Triolo, M. & Hood, D. A. Impact of aging and exercise on mitochondrial quality control in skeletal muscle. Oxid. Med. Cell. Longev. 2017, 3165396 (2017).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"679_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.abb.2007.03.034","volume":"462","author":"I Kim","year":"2007","unstructured":"Kim, I., Rodriguez-Enriquez, S. & Lemasters, J. J. Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 462, 245\u2013253 (2007).","journal-title":"Arch. Biochem. Biophys."},{"key":"679_CR35","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1128\/MCB.25.3.1025-1040.2005","volume":"25","author":"P Boya","year":"2005","unstructured":"Boya, P. et al. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 25, 1025\u20131040 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"679_CR36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.4161\/auto.6.6.12397","volume":"6","author":"J Li","year":"2010","unstructured":"Li, J. et al. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy 6, 711\u2013724 (2010).","journal-title":"Autophagy"},{"key":"679_CR37","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/(SICI)1098-2795(199708)47:4<468::AID-MRD14>3.0.CO;2-S","volume":"47","author":"RJ Aitken","year":"1997","unstructured":"Aitken, R. J. et al. Reactive oxygen species generation by human spermatozoa is induced by exogenous NADPH and inhibited by the flavoprotein inhibitors diphenylene iodonium and quinacrine. Mol. Reprod. Dev. 47, 468\u2013482 (1997).","journal-title":"Mol. Reprod. Dev."},{"key":"679_CR38","first-page":"514261","volume":"2011","author":"CP Miller","year":"2011","unstructured":"Miller, C. P., Singh, M. M., Rivera-Del Valle, N., Manton, C. A. & Chandra, J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J. Biomed. Biotechnol. 2011, 514261 (2011).","journal-title":"J. Biomed. Biotechnol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0679-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T17:42:49Z","timestamp":1751650969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0679-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0679-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"24 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"589"}}